Tocilizumab in refractory rheumatoid arthritis: long-term efficacy, safety, and tolerability beyond 2 years
Biologics: Targets and Therapy · 2016
DOI: 10.2147/btt.s101289 ↗Kurz gefasst
Fachartikel in der Zeitschrift Biologics: Targets and Therapy, 2016. Verfasst von Ziad Farah und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Rheumatology, Charing Cross Hospital, London, UK. Die Arbeit wurde bisher 5-mal zitiert (Crossref). Der Volltext ist frei zugänglich (Open Access, CC BY-NC 3.0).
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Rheumatology, Charing Cross Hospital, London, UK.
Zitieren
APA
Farah, Z., Ali, S., Price-Kuehne, F., & Mackworth-Young, C. G. (2016). Tocilizumab in refractory rheumatoid arthritis: long-term efficacy, safety, and tolerability beyond 2 years. Biologics: Targets and Therapy. https://doi.org/10.2147/btt.s101289
Vancouver
Farah Z, Ali S, Price-Kuehne F, Mackworth-Young CG. Tocilizumab in refractory rheumatoid arthritis: long-term efficacy, safety, and tolerability beyond 2 years. Biologics: Targets and Therapy. 2016. doi:10.2147/btt.s101289
BibTeX
@article{Farah2016,
author = {Farah, Ziad and Ali, Sabreen and Price-Kuehne, Fiona and Mackworth-Young, Charles G},
title = {Tocilizumab in refractory rheumatoid arthritis: long-term efficacy, safety, and tolerability beyond 2 years},
journal = {Biologics: Targets and Therapy},
year = {2016},
doi = {10.2147/btt.s101289}
}
EUVIMED